Axel Grothey, MD, medical oncologist and our Director of Gastrointestinal Cancer Research, discusses the role of precision medicine in colorectal cancer (CRC) with OncLive.

Grothey says, “With the rise of molecular profiling, the field of CRC has shifted away from a one-size-fits-all approach and entered an era of precision medicine. Notably, molecular profiling guides the treatment selection process and allows for better patient outcomes. As such, it should be utilized across all advanced gastrointestinal malignancies.”

“A number of targeted agents directed toward specific mutations are available in CRC. These regimens should be used to tailor effective treatment to an individual patient. In addition, these therapies tend to be well tolerated and many patients who receive them are able to maintain a good quality of life.”


Click here to watch the full video interview.